Johnson & Johnson negotiating to buy biotech company Centocor
This article was originally published in Clinica
Johnson & Johnson is believed to be in talks to acquire the US biotech firm, Centocor, in a share deal valued at more than $3 billion. Shares in Centocor, which have already risen sharply in recent weeks on takeover rumours, climbed a further $1.75 to $48.63 on May 4. Both companies declined to comment on the potential acquisition.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.